Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine

Francesco Fontana1, Gaetano Alfano1,2, Giacomo Mori1, Alessio Amurri2, Lorenzo Tei2, Marco Ballestri1, Marco Leonelli1, Francesca Facchini1, Francesca Damiano1, Riccardo Magistroni1,2, Gianni Cappelli1,2

1Struttura Complessa di Nefrologia e Dialisi, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
2Surgical Medical and Dental Department of Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy

Correspondence
Francesco Fontana
Email: francesco.fontana@unimore.it

Coronavirus disease 2019 (COVID-19) pneumonia has been poorly reported in solid organ transplanted patients; prognosis is uncertain and best management unclear. We describe the case of a 61-year-old kidney transplant recipient with several comorbidities who was hospitalized and later received a diagnosis of COVID-19 pneumonia; the infection was successfully managed with the use of hydroxychloroquine and a single administration of tocilizumab, after immunosuppression reduction; the patient did not require mechanical ventilation. During the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, transplant clinicians should be readily informed about new cases of COVID-19 pneumonia in solid organ transplant recipients, with focus on therapeutic strategies employed and their outcome.

KEYWORDS
clinical research/practice, immunosuppressant – fusion proteins and monoclonal antibodies, infection and infectious agents – viral, infectious disease, kidney transplantation/nephrology

1 | BACKGROUND

In late December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as a novel pathogen causing severe pneumonia cases, lately named coronavirus disease 2019 (COVID-19), in Wuhan, China. Since then, the infection has been demonstrating a rapid global spread, with a devastating evolution in northern Italy; there, several simultaneous clusters developed with a substantial number of critically ill patients and a very high case fatality rate, especially among the elderly and those with comorbidities. COVID-19 is considered as potentially having a more severe course in solid organ transplant recipients, due to the chronic immunosuppression these patients are exposed to for preventing rejection. Only a few reports of COVID-19 in kidney transplanted patients are currently available in the literature, and prognosis and recommended management for these patients are unclear. Moreover, the impact of treatments other than best supportive care is unknown.

2 | CASE REPORT

A 61-year-old man, who underwent kidney transplantation from a deceased donor in 2005 for end-stage renal disease due to chronic interstitial nephritis, was admitted to the nephrology unit for persistent fever and shivering over the last 48 hours. He reported no cough or dyspnea, he had not traveled outside town in the past 15 days, and had no history of contact with people positive or suspected for SARS-Cov-2 infection.

The patient had chronic kidney disease stage IIIa (serum creatinine 1.5 mg/dL, estimated glomerular filtration rate of 50 mL/min); maintenance immunosuppression consisted of cyclosporine A (CyA) plus steroid. Past medical history included nodal marginal zone

Abbreviations: COVID-19, coronavirus disease 2019; CyA, cyclosporine A; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
lymphoma in active hematological surveillance; previous unpro-
voked pulmonary embolism treated with warfarin in secondary pre-
vention; and idiopathic Parkinson disease with motor complications
treated with subthalamic neurostimulation, with neurogenic bladder
managed with intermittent bladder catheterization and complicated
by frequent urinary tract infections.

At first evaluation, physical examination was unremarkable
(apart from tremor related to chronic neurological condition);
blood pressure was 136/72 mm Hg, and body temperature was
38°C; peripheral capillary oxygen saturation was 97% breathing
ambient air. Laboratory blood tests were normal with blood cell
count (5460 cells/mm³ with 79% neutrophils), mild acute kid-
ney injury (serum creatinine 1.9 mg/L), and minimally elevated
C-reactive protein (4.1 mg/dL); CyA levels were 90 ng/mL (basal)
and 136 ng/mL (after 2 hours). Chest radiography showed mini-
mal left pleural effusion. Specimens for urinary and blood cultures
were collected; urinary tract infection was suspected and antibi-
otic treatment with meropenem was initiated, based on a previous
isolate.

On day 3 after admission, considering persistence of fever, neg-
ativity of urinary cultures and serum procalcitonin, SARS-CoV-2
infection was suspected and the patient isolated in a single room.
Antibiotic treatment was stopped, oropharyngeal/nasal swab for
SARS-CoV-2 research in reverse transcription polymerase chain
reaction (RT-PCR) was performed; a repeated chest radiograph
showed bilateral basal interstitial pneumonia; arterial blood gases
were unremarkable (pO₂ 91 mm Hg breathing ambient air). In the
following days, the patient remained stable with undulating fever
and no dyspnea. Search for viral and bacterial pathogens in PCR
from upper respiratory tract material resulted negative, as were
cytomegalovirus DNA on blood and blood cultures collected at
admission. Diagnostic oropharyngeal/nasal swabs for SARS-CoV-2
were repeated and, only at the third attempt on day 9 after admis-
sion, the test was positive. In the same week 3 other hospitalized
patients and, the week after, 2 healthcare workers resulted pos-
itive for SARS-CoV-2 infection in our service; nevertheless, even
if cases were probably related, it was not possible to track a clear
chronological order.

On the day of diagnosis, arterial pO₂ dropped to 57 mm Hg, and
low-flow oxygen through nasal cannula was initiated; the patient
was hemodynamically stable. Hydroxychloroquine was started at
the dose of 200 mg bid; CyA dose was reduced by a half; intrave-
nous fluids were initiated. Laboratory exams showed leukopenia
with lymphopenia (see Figure 1); serum lactate dehydrogenase,
hemoglobin, platelets, and D-dimer levels were normal. Two days
after, considering the lack of improvement in clinical conditions,
CyA was withdrawn and oral steroid dose increased (methylpred-
nisolone 16 mg per day); after discussion with infectious disease
specialist and signature of informed consent by the patient, tocili-
zumab was administered off label at the dose of 324 mg via subcu-
taneous route. Interleukin-6 (IL-6) levels in blood proved to be high
(280.86 pg/mL).

**FIGURE 1** Trends of body temperature (°C), arterial pO₂
(mm Hg), and peripheral oxygen saturation (SO₂, %); leukocytes
and lymphocyte counts (absolute number/µL); C-reactive protein
(mg/dL); serum creatinine (mg/dL) and estimated glomerular
filtration rate (eGFR) according to Chronic Kidney Disease
Epidemiology Collaboration (mL/min). Timing of administration
of tocilizumab, hydroxychloroquine (HCQ), and intravenous
immunoglobulins (IVIG) and withdrawal of cyclosporin (CyA) are
reported in the top part of the figure.
The patient developed progressive leukopenia (with leukocyte nadir at 660/µL, neutrophils 400/µL). Suspecting that leukopenia with neutropenia could be an immune-mediated process related to tocilizumab, and in order to enhance anti-inflammatory and immunomodulatory response, we administered intravenous immunoglobulins (IVIG) at the dose of 0.3 g/kg. Leukocyte count rose to 2090/µL (neutrophils 1180/µL, lymphocytes 670/µL), with CD4 count 518/µL.

On day 14 after admission, urinary culture was positive for multiresistant Pseudomonas aeruginosa, and, considering the risk for bacterial disseminated infection after tocilizumab, antibiotic treatment with meropenem was reinitiated. On day 14, chest radiograph showed multiple nonhomogeneous bilateral consolidations, and azithromycin was administered orally for 3 days to prevent bacterial superinfection. The radiographic picture was interpreted as imaging evolution of COVID-19 pneumonia.

Since tocilizumab administration, the patient remained apyretic. Arterial pO2 showed progressive improvement with values always above 60 mm Hg, and oxygen treatment was stopped. IL-6 levels increased, as expected, 6 days after administration of tocilizumab (619.11 pg/mL).

Kidney function remained substantially stable over the course of hospitalization (Figure 1).

The patient was discharged home on day 22 after admission without fever and with peripheral oxygen saturation of 95% breathing ambient air; respiratory frequency was 14 acts per minute, blood pressure was 140/80 mm Hg; white blood cell count was 2970/µL. Oropharyngeal/nasal swab for SARS-Cov-2 was still positive 11 days after diagnosis, and appropriate isolation measures were recommended at home. Hydroxychloroquine was stopped, and CyA is presently still withheld.

3 | DISCUSSION

The world is now facing a pandemic of SARS-CoV-2 infection causing COVID-19, which is unique in terms of rapidity of growth and global involvement; no proven specific therapies are available, other than supportive care. Emerging infectious diseases represent an enormous threat of contagion to transplant recipients; these patients, in turn, are subjected to frequent ambulatory checks and hospitalizations and they can substantially contribute to the spreading of the infection if not promptly identified.

Clinical presentation of COVID-19 is nonspecific, most of the time manifesting as a febrile illness with often mild upper respiratory manifestations. Symptoms and signs can be very subtle especially in the early phases of the infection, requiring a high degree of suspicion by clinicians and imposing logistic challenges in order to isolate suspected cases.

Our report shows potential limitations in the diagnosis of SARS-CoV-2 infection with a single oropharyngeal/nasal swab. Although RT-PCR diagnostic for SARS-CoV-2 infection has been described to be extremely sensitive,8 false negative results on oropharyngeal/nasal swab have been reported.9 It is postulated that several mechanisms can be responsible for this phenomenon, among them sampling techniques, timing of viral positivity after initial infection, and lack of expression of angiotensin-converting enzyme 2 (functional receptor of SARS-CoV-2) in nasal and pharyngeal mucosa.10,11 It appears then important to perform repeated oropharyngeal/nasal swabs, or consider obtaining bronchoalveolar lavage material if initial testing is negative, in patients with a consistent clinical suspicion for SARS-CoV-2 infection. Moreover, even in the absence of positive RT-PCR positivity, clinical indicators (especially suggestive radiologic imaging) should guide clinical diagnosis indicating need for isolation of the patient.12

The optimal management of a solid organ transplant recipient with SARS-CoV-2 infection is not clearly determined. It seems rational to reduce the immunosuppressive load, as it is common practice in most severe infections in transplanted patients; in general, our protocol is to withdraw mycophenolate mofetil and, as a second step, reduce and consider stopping calcineurin inhibitor. Nevertheless, because a great part of the pulmonary damage in COVID-19 pneumonia appears to be related to excessive inflammatory response of the host,13 it could be argued that antirejection drugs could contribute to reducing this process.

In our patient, we decided to reduce cyclosporine dose by half and later stop it, also considering the high risk for bacterial infection, maintaining low-dose steroid.

Several drugs are being administered off label and are currently under investigation in clinical trials for COVID-19.

There is mounting enthusiasm regarding the use of chloroquine and its analog hydroxychloroquine against SARS-CoV-2. Rationale for its use derived from in vitro studies from China demonstrating that chloroquine was able to block virus infection at low-micromolar concentration in vitro and possessed high selectivity index.14 Recently, a small nonrandomized clinical trial from France showed that infected patients treated with hydroxychloroquine were more likely to achieve virologic clearance at day 6;15 nevertheless, this study has received extensive criticism about its methodology and its results have been described as overstating.16 Despite poor quality evidence, given the lack of alternative effective treatments, the relatively safe toxicity profile and its wide availability, many centers in Italy have adopted hydroxychloroquine as a first-line strategy in patients with confirmed SARS-Cov-2 infection. In our patient, hydroxychloroquine was continued for a total of 13 days.

It is believed that the severity of pulmonary involvement in SARS-CoV-2 infection is mainly driven by an excessive inflammatory response mounted by the host immune system in response to pathogen. Indeed, inflammation-related indices have been reported to be higher in patients with COVID-19 pneumonia who develop acute respiratory distress syndrome compared to those who do not; interestingly, IL-6 was significantly more elevated in these patients.13 IL-6 is a multifunctional proinflammatory cytokine which stimulates T cell proliferation/differentiation to T helper cells and differentiation of B-lymphocytes to antibody-secreting plasma cells.17 Tocilizumab is a humanized monoclonal antibody that competitively inhibits IL-6 by binding to both its soluble and membrane receptors;17 its use in COVID-19 pneumonia is...
currently being investigated in a multicenter, single-arm, open-label, phase 2 study in Italy.18

In order to reduce pulmonary inflammatory response, we decided to administer tocilizumab in our patient in an early phase, before overt lung damage ensued; our strategy was also supported by demonstrating high levels of IL-6 in blood. The subcutaneous route of administration was chosen according to local stock availability, because intravenous formulation was rapidly exhausted. Administered dose was double that recommended for rheumatoid arthritis and was chosen in the attempt to mimic pharmacodynamics of the intravenous administration. There is no clear consensus regarding a definite schedule of tocilizumab administration in COVID-19; main contraindications to tocilizumab are untreated active infection, aspartate transaminase/alanine transaminase elevation, neutrophil count <500/µL, and platelets <50 000/µL. Considering the good clinical response in our patient, we decided not to proceed with additional doses. It must be clarified that an increase in serum IL-6 levels was expected after tocilizumab administration; because IL-6 receptor is fully inhibited, the produced ligand will remain in the circulation until degradation. This phenomenon does not correspond to a lack in tocilizumab efficacy, because the IL-6 signaling pathway is expected to be completely blocked; IL-6 levels are expected to gradually decrease over time.

In addition to that, the patient was also treated with IVIG for leukopenia with neutropenia possibly related to tocilizumab and to counteract aberrant inflammation related to COVID-19. Indeed, tocilizumab have been reported to induce neutropenia, considered to be immune mediated.19 Moreover, IVIG possess anti-inflammatory and immunomodulatory effects; several are the postulated mechanisms, among them the decrease in the production of proinflammatory cytokines,20 which could have been of benefit in our case, considering the pathogenesis of pulmonary damage in COVID-19.

Because oropharyngeal/nasal swab was still positive for SARS-CoV-2 at discharge, CyA treatment was not resumed; the patient is currently monitored and CyA will be re instituted after demonstrating absence of viral shedding.

In conclusion, we report a case of COVID-19 pneumonia in a kidney transplant recipient with several comorbidities, which was successfully managed with the use of multiple pharmacological treatments (hydroxychloroquine, IVIG, and a single dose of tocilizumab) and reduction of immunosuppression. The patient had no need for mechanical ventilation. We acknowledge that results obtained in a single case are difficult to generalize, considering the multiple drugs involved and the unclear natural course of COVID-19 in transplanted patients. Nevertheless, we consider that transplant clinicians should be aware of potentially useful pharmacological treatments for COVID-19 pneumonia in solid organ transplant recipients. Given the extremely fast growth of the epidemic of SARS-CoV-2 worldwide, we believe it is of paramount importance to report management of cases in special populations, before results of large clinical trials become available.

DISCLOSURE
The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

DATA AVAILABILITY STATEMENT
Data are available upon request to the corresponding author.

ORCID
Francesco Fontana https://orcid.org/0000-0003-0762-0942
Gaetano Alfano https://orcid.org/0000-0003-0591-8622

REFERENCES
1. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;NEJMoa2002032. https://doi.org/10.1056/NEJMoa2002032.
2. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy [published online ahead of print 2020]. JAMA. 2020. https://doi.org/10.1001/jama.2020.4683
3. Zhu L, Xu X, Ma K, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. [published online ahead of print 2020]. Am J Transplant2020. https://doi.org/10.1111/ajt.15869.
4. Guillen E, Pineiro GJ, Revuelta I, et al. Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? [published online ahead of print 2020]. Am J Transplant 2020. https://doi.org/10.1111/ajt.15874.
5. Seminari E, Colaneri M, Sambo M, et al. SARS Cov2 infection in a renal transplanted patients. A case report. [published online ahead of print 2020]. Am J Transplant 2020. https://doi.org/10.1111/ajt.15902.
6. Gandolfini I, Delsante M, Fiaccadori E, et al. COVID-19 in kidney transplant recipients [published online ahead of print 2020]. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15891.
7. Huang J, Lin H, Wu Y, et al. COVID-19 in post-transplantation patients- report of two cases [published online ahead of print 2020]. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15896.
8. Chan JF-W, Yip CC-Y, To KK-W, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens. J Clin Microbiol. 2020;JCM.00310-20. https://doi.org/10.1128/JCM.00310-20.
9. Winichakoon P, Chaiwarith R, Liwrisakun C, et al. Negative nasopharyngeal and oropharyngeal swab does not rule out COVID-19 [published online ahead of print 2020]. J Clin Microbiol. 2020. https://doi.org/10.1128/JCM.00297-20.
10. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020;94(7). https://doi.org/10.1128/JVI.00297-20.
11. Hamming I, Timens W, Bult/arches MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637.
12. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19 [published online ahead of print 2020]. J Med Virol. 2020. https://doi.org/10.1002/jmv.25786.
13. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China [published online ahead of print 2020]. JAMA Intern Med. 2020. https://doi.org/10.1001/jamainternmed.2020.0994.
14. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30(3):269-271.

15. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print 2020]. *Int J Antimicrob Agents.* 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949.

16. Dahly D, Gates S, Morris T. Statistical review of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print 2020]. Zenodo. 2020 https://doi.org/10.5281/ZENODO.3725560.

17. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. *Blood.* 2008;112(10):3959-3964.

18. Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/study/NCT04317092?term=tocilizumab&cond=covid&draw=2&rank=1. Accessed March 24, 2020.

19. Shovman O, Shoenfeld Y, Langevitz P. Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature. *Immunol Res.* 2014;61(1-2):164-168.

20. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. *N Engl J Med.* 2012;367(21):2015-2025.

*How to cite this article:* Fontana F, Alfano G, Mori G, et al. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. *Am J Transplant.* 2020;20:1902–1906. https://doi.org/10.1111/ajt.15935